Imagen de Portada

The carbon footprint of transperineal prostate biopsy

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Daniel A. Carson, Ali Hooshyari, Jesse Gale, Greg Evans, Flavio V. Ordones, Lodewikus P. Vermeulen
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	BJUI Compass
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Perioperative antibiotic prophylaxis, prostate size and transperineal prostate biopsy
por: Maxwell Louis Sandberg, et al.
Publicado: (2026)

Concordance with final pathology when transitioning from standard transrectal to cognitive targeted transperineal prostate biopsy
por: Alfred Honoré, et al.
Publicado: (2025)

Impact of multiparametric MRI and prostate biopsies on anxiety and quality of life in men with suspected prostate cancer
por: Esther H. J. Hamoen, et al.
Publicado: (2025)

Quantification of perineural invasion on prostate biopsy improves risk stratification in biopsy Grade Group 2–3 cancer
por: Yuki Teramoto, et al.
Publicado: (2026)

AI‐enhanced micro‐ultrasound improves detection of clinically significant prostate cancer at biopsy
por: Muhammad Imran, et al.
Publicado: (2026)

Risk factors of negative prostate biopsies: A CHAID decision tree analysis
por: Pierre Allainguillaume, et al.
Publicado: (2026)

Perioperative alpha blockers in voiding dysfunction secondary to prostate biopsy: A meta‐analysis
por: Sean Lim, et al.
Publicado: (2024)

The impact of pre‐biopsy MRI and additional testing on prostate cancer screening outcomes: A rapid review
por: Abel Tesfai, et al.
Publicado: (2024)

Transperineal prostate biopsy with freehand technique under local anaesthetic: A systematic review and meta‐analysis
por: Benjamin M. Mac Curtain, et al.
Publicado: (2025)

Clinical validation of a biopsy‐based six‐gene signature prognostic for aggressive prostate cancer
por: Agnieszka Krzyzanowska, et al.
Publicado: (2024)

Omission of contralateral biopsies in unilateral MRI‐suspicious prostate cancer has minimal impact on clinical risk assessment
por: Stijn M. van den Bosch, et al.
Publicado: (2026)

Cost‐effectiveness analysis of a biopsy‐free diagnostic strategy for prostate cancer using mpMRI and PSMA‐PET/CT
por: Joshua Yi Min Tung, et al.
Publicado: (2026)

Performance and safety of transverse scrotal vs transperineal AUS for PPUI: A retrospective cohort study
por: Christine R. Reus, et al.
Publicado: (2025)

The impact of biopsy core length on the discrepancy in Gleason scores between biopsy and radical prostatectomy specimen
por: Cheng‐hao Guo, et al.
Publicado: (2025)

Genomic prostate score and treatment selection in favourable intermediate‐risk prostate cancer
por: Eric Margolis, et al.
Publicado: (2025)

Variation in harms and benefits of prostate‐specific antigen screening for prostate cancer by socio‐clinical risk factors: A rapid review
por: Abel Tesfai, et al.
Publicado: (2024)

Contemporary assessment of diagnostic performance and histologic concordance of renal mass biopsy with surgical pathology
por: Mitchell M. Huang, et al.
Publicado: (2025)

Utility of dynamic contrast enhancement for clinically significant prostate cancer detection
por: Eric V. Li, et al.
Publicado: (2024)

‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer
por: Ryan Sutherland, et al.
Publicado: (2024)

A modified Delphi consensus statement on the role of biopsy in small renal masses
por: Darryl E. Bernstein, et al.
Publicado: (2025)

Emerging tools for the early detection of prostate cancer
por: Muhammad Haider, et al.
Publicado: (2025)

Quality of English‐ and Spanish‐language online content about prostate cancer genetics: Insights into potential contributors to prostate cancer disparities
por: Sophia M. Abusamra, et al.
Publicado: (2025)

Comparing outcomes of Aquablation versus holmium laser enucleation of prostate in the treatment of benign prostatic hyperplasia: A network meta‐analysis
por: Ansh Bhatia, et al.
Publicado: (2024)

Bibliometric analysis of focal therapy in prostate cancer research
por: Mohammed Shahait, et al.
Publicado: (2024)

Does total lesion prostate‐specific membrane antigen (PSMA) activity on 68Ga‐PSMA PET/CT correlate with PSA and prostatectomy histopathological/clinical outcomes in patients with localised primary prostate cancer?
por: Jeremy Cheng, et al.
Publicado: (2025)

WATER versus WATER II 5‐year update: Comparing Aquablation therapy for benign prostatic hyperplasia in 30–80‐cm3 and 80–150‐cm3 prostates
por: Mohamad Baker Berjaoui, et al.
Publicado: (2024)

Association between beta‐blocker atenolol use and prostate cancer upgrading in active surveillance1
por: Ali H. Zahalka, et al.
Publicado: (2024)

Multivariable model integrating PHI and mpMRI for detecting csPCa in biopsy‐naïve men
por: Mario Dominguez Esteban, et al.
Publicado: (2025)

Micro‐ultrasound tissue echogenicity predicts prostate cancer grade
por: Ailene E. Corona, et al.
Publicado: (2026)

The impact of vaporization on adenoma weight in benign prostatic hyperplasia surgery
por: André B. Silva, et al.
Publicado: (2026)

Extracapsular extension risk assessment using an artificial intelligence prostate cancer mapping algorithm
por: Alan Priester, et al.
Publicado: (2024)

Sociodemographic landscape of suspected prostate cancer referrals and diagnoses across North East London
por: Muhammad Haider, et al.
Publicado: (2025)

Focal therapy in prostate cancer: Development, application and outcomes in the United Kingdom
por: Nadia Rokan, et al.
Publicado: (2025)

Multidisciplinary meetings for lower urinary tract symptoms and benign prostate hyperplasia
por: Emilien Seizilles de Mazancourt, et al.
Publicado: (2025)

Targeting genomic receptors in voided urine for confirmation of benign prostatic hyperplasia
por: Mathew Thakur, et al.
Publicado: (2024)

National survey of urologists' views on prostate cancer screening in the United Kingdom
por: Nikhil Mayor, et al.
Publicado: (2026)

Investigating the prognostic utility of GSTP1 promoter methylation in prostate cancer
por: Ruth Pidsley, et al.
Publicado: (2024)

PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer
por: Nicole Handa, et al.
Publicado: (2025)

Influences on androgen deprivation therapy prescribing before surgery in high‐risk prostate cancer
por: Jennifer Dunsmore, et al.
Publicado: (2024)

The significant costs of prostate cancer management—An analysis from a Caribbean hospital
por: Geneva Pantoja, et al.
Publicado: (2025)